Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure Feb. 9, 2017 No Comments
Promising phase III topline results for CAM-2038 to treat moderate to severe opioid use disorder Nov. 14, 2016 No Comments
Omeros reports on phase II trial of PPARgamma agonist in heroin-dependent subjects Nov. 3, 2016 No Comments
Hawaii Biotech describes new Botulinum neurotoxin type A light chain inhibitors Oct. 31, 2016 No Comments
Omeros reports results from phase II study of PPARgamma agonist in cocaine use disorder Oct. 20, 2016 No Comments
RSS